Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome

Rheumatology

Volumn 42, Issue 7, 2003, Pages 893-899

  Delgado Alves, J ^a,b   Kumar, S ^a   Isenberg, D A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Centre for Rheumatology   (United Kingdom)

Author keywords

Anti Apo A I; Anti HDL; Antiphospholipid syndrome; Atherosclerosis; Cross reactivity; Systemic lupus erythematosus

Indexed keywords

APOLIPOPROTEIN A1; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; STEROID; WARFARIN; AUTOANTIBODY; IMMUNOGLOBULIN G;

ADULT; ANTIBODY ISOLATION; ANTIBODY TITER; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROSCLEROSIS; BINDING ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN TARGETING; SYSTEMIC LUPUS ERYTHEMATOSUS; IMMUNOLOGY; METHODOLOGY;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; APOLIPOPROTEIN A-I; AUTOANTIBODIES; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIPOPROTEINS, HDL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE;

EID: 0041569770     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg248     Document Type: Article

References (29)

1. Morrow J, Nelson L, Watts R, Isenberg D. Systemic lupus erythematosus. In: Autoimmune rheumatic disease. Oxford: Oxford University Press, 1999:56-103.
2. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
3. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986;13:486-9.
4. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
5. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein 1 structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457-62.
6. McIntyre JA, Wagenknecht DR, Sugi T. Phospholipid binding plasma proteins required for antiphospholipid antibody detection - an overview. Am J Reprod Immunol 1997;37:101-10.
7. Triplett DA. Many faces of lupus anticoagulants. Lupus 1998;7(Suppl. 2):S18-S22.
8. el Roeiy A, Valesini G, Friberg J et al. Autoantibodies and common idiotypes in men and women with sperm antibodies. Am J Obstet Gynecol 1988;158:596-603.
9. Lanir N, Zilberman M, Yron I, Tennenbaum G, Shechter Y, Brenner B. Reactivity patterns of antiphospholipid antibodies and endothelial cells: effect of antiendothelial antibodies on cell migration. J Lab Clin Med 1998; 131:548-56.
10. Mizutani H, Kurata Y, Kosugi S et al. Monoclonal anticardiolipin autoantibodies established from the (New Zealand white × BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum 1995;38:1382-8.
11. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60:221-5.
12. MacGregor AJ, Dhillon VB, Binder A et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992;51:152-5.
13. Ames PR, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J. Oxidative stress in systemic Jupus erythematosus and allied conditions with vascular involvement. Rheumatology 1999;38:529-34.
14. Borba EF, Bonfa E. Dyslipoproteinemias in systemic Jupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997;6:533-9.
15. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987; 83:503-8.
16. Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993;36:1566-74.
17. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-5.
18. Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 1998;7:355-60.
19. Vaarala O, Puurunen M, Lukka M et al. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Clin Exp Immunol 1996;104:269-74.
20. Deguchi H, Fernandez JA, Hackeng TM, Banka CL, Griffin J-H. Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci USA 2000; 97:1743-8.
21. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
22. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
23. Zhu M, Olee T, Le DT et al. Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Br J Haematol 1999; 105:102-9.
24. Harris EN, Hughes GR. Standardising the anti-cardiolipin antibody test. Lancet 1987;1:277.
25. Mackness MI, Durrington PN. Lipoprotein analysis - A practical approach. Oxford: IRL Press, 1992.
26. Delgado AJ, Ames PR, Donohue S et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002;46:2686-94.
27. Vaarala O. Antibodies to oxidised LDL. Lupus 2000; 9:202-5.
28. Libby P. Atherosclerosis. In: Fauci AS, Braunwald E, Isselbacher KJ et al., eds. Harrison's principles of internal medicine. New York: McGraw-Hill, 1998:1345-52.
29. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19:2214-25.